a balanced article which also points out discontinuations and variable benefits. Not sure I'm more confident having read this although given no other treatment is available a case by case use would seem reasonable given safety is fine. This would then mean fda might lean towards approval. - I hope for all concerned.
a balanced article which also points out discontinuations and...
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$14.96 |
Change
0.200(1.36%) |
Mkt cap ! $1.857B | |||
| Open | High | Low | Value | Volume |
| $14.94 | $15.11 | $14.82 | $1.720M | 115.1K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 7 | 465 | $14.93 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $14.96 | 188 | 5 |
View Market Depth
| Last trade - 12.07pm 17/07/2025 (20 minute delay) ? |
| NEU (ASX) Chart |